Stoke Therapeutics, Inc. (STOK) Deep Dive Video

Name: Stoke Therapeutics, Inc. (STOK) Deep Dive Video | Flash
Uploaded: 2026-07-07T01:08:31.120Z
Description: Stoke Therapeutics offers a high-risk, asymmetric bet that zorevunersen can become the first disease-modifying Dravet therapy, with Biogen-backed funding and pivotal Phase 3 catalysts setting up a decisive 2027 inflection.

Stoke Therapeutics, Inc. (STOK) video thumbnail

Summary

Stoke Therapeutics offers a high-risk, asymmetric bet that zorevunersen can become the first disease-modifying Dravet therapy, with Biogen-backed funding and pivotal Phase 3 catalysts setting up a decisive 2027 inflection.

View STOK stock page · Read the STOK research report

Loading the video player…

Loading Flash…